

HIGHLIGHT ADVISORS

DAVID BLAUSTEIN

THE GALLEON GROUP,
NEW YORK, NY, USA

ERIK DE CLERCQ

KATHOLIEKE UNIVERSITEIT
LEUVEN, BELGIUM

RODERICK FLOWER

WILLIAM HARVEY RESEARCH
INSTITUTE, QMW, LONDON, UK

F. PETER GUENGERICH

VANDERBILT UNIVERSITY
NASHVILLE, TN, USA

FRANZ HEFTI

RINAT NEUROSCIENCE
CORPORATION, PALO ALTO,
CA, USA

JOAN HELLER BROWN

UNIVERSITY OF CALIFORNIA
SAN DIEGO, CA, USA

MADS KROGSGAARD THOMSEN

NOVO NORDISK, BAGSVAERD,
DENMARK

HUGO KUBINYI

UNIVERSITY OF HEIDELBERG,
GERMANY

JULIO LICINIO

UNIVERSITY OF CALIFORNIA
LOS ANGELES, CA, USA

CHRISTOPHER LIPINSKI

PFIZER GLOBAL RESEARCH
AND DEVELOPMENT, GROTON,
CT, USA

LESLIE MEYER-LEON

IP LEGAL STRATEGIES GROUP,
CAPE COD, MA, USA

TOMI SAWYER

ARIAD PHARMACEUTICALS,
CAMBRIDGE, MA, USA

GEORGE SCHLICH

MATHYS & SQUIRE,
LONDON, UK

JANET WOODCOCK

CENTER FOR DRUG
EVALUATION AND RESEARCH,
WASHINGTON, MD, USA

NEURODEGENERATIVE DISEASE


Putting the brakes on cognitive decline

Central to the amyloid hypothesis of Alzheimer's disease is the primary role of aggregated β -amyloid ($A\beta$) peptide in causing the pathogenesis and loss of cognitive function characteristic of the disease. But the fashionability of $A\beta$ as a potential therapeutic target suffered a setback last year when Elan/Wyeth-Ayerst's much heralded clinical trial of passive immunization against $A\beta$ as a treatment for Alzheimer's disease was halted due to the development of adverse reactions in a subset of patients. At the time, the paucity of information surrounding the reasons for interrupting the trial only increased concern about the validity of the approach, and it was subsequently revealed that 6% of patients had developed a potentially life-threatening aseptic meningoencephalitis. Although the trial remains suspended, a paper in the 22 May issue of *Neuron* now reports reduced cognitive decline in a small cohort of enrolled patients that developed a high titre of antibodies to $A\beta$.

The study by Hock *et al.* describes results obtained from the Zurich cohort of the Phase IIa multicentre trial, which represents just 30 patients out of a total of 300. Of these, 24 had received an intramuscular injection of pre-aggregated synthetic $A\beta_{42}$, together with adjuvant to stimulate an immune response, followed by a booster injection one month later. Placebo had been given to the

remaining six patients, and investigators were not informed of the drug/placebo status of any of the trial group. The cognitive abilities of this patient population were followed over the course of the year following immunization, with neuropsychological assessment being carried out at baseline and after eight and twelve months. Measures of cognitive status were then correlated with the development of antibodies to $A\beta$ plaques, quantitatively assessed using a specially designed tissue amyloid plaque immunoreactivity assay, which measures the immunoreactivity of human sera for $A\beta$ plaques in fixed tissue sections taken from the brains of a mouse model of Alzheimer's disease.

Of the twenty-eight patients still enrolled after a year (there were two dropouts), the nineteen who generated antibodies against $A\beta$ were found to perform significantly better in neuropsychological tests after eight and twelve months than the nine patients that did not show immunoreactivity. Overall, Mini Mental State Examination (MMSE) scores in the antibody-producing patients remained unchanged during the course of the year, indicating no significant cognitive decline by this measure. Cognitive status reported by the patients' caregivers, measured by the Disability Assessment for Dementia rating scale, also showed significantly



less decline in the immunoreactive population. However, the MMSE scores for the group that did not produce antibodies declined significantly more than would be expected for an untreated population, an observation which emphasizes the risks of over interpreting data gleaned from such a small sample of patients.

The finding that sustained production of serum antibodies generated against $A\beta$ plaques can slow cognitive deterioration is key evidence for the involvement of $A\beta$ in Alzheimer's disease progression. This good news is somewhat tempered by the reported development of aseptic meningoencephalitis in three of the Zurich patients, although two of these patients did exhibit serum immunoreactivity and improved cognitive function.

Adam Smith

References and links

ORIGINAL RESEARCH PAPER Hock, C *et al.* Antibodies against β -amyloid slow cognitive decline in Alzheimer's disease. *Neuron* **38**, 547–554 (2003)